High B7-H3 expression is linked to increased risk of prostate cancer progression
High B7-H3 expression is linked to increased risk of prostate cancer progression
复制标题
DOI：
10.1111/pin.12999
复制
发表时间：
2020-08-10
影响因子：
2.2
通讯作者：
Weideman, Soeren A.
中科院分区：
文献类型：
--
作者：
Bonk, Sarah;Tasdelen, Pinar;Weideman, Soeren A.
B7-H3是免疫检查点分子B7超家族的成员。B7-H3上调与包括前列腺癌在内的许多肿瘤的癌症发展和进展有关。为了阐明B7-H3作为预后生物标志物的潜在效用，通过免疫组织化学分析了17000多例前列腺癌中B7-H3的表达。正常的前列腺腺大部分是B7-H3阴性，而膜B7-H3免疫染色被认为是在47.0%的分析癌症。12.3%的病例B7-H3免疫染色为弱阳性，21.1%为中度阳性，13.5%为强阳性。B7-H3高表达与pT、Gleason评分、淋巴结转移、Ki 67高标记指数和早期前列腺特异性抗原复发相关（均P < 0.0001）。B7-H3高表达也与雄激素受体高表达和TMPRSS 2：V-ets禽成红细胞增多症病毒E26癌基因同源物（ERG）融合有关（均P < 0.0001）。多变量分析显示，在所有癌症和ERG阴性亚组中，B7-H3高表达对预后有很强的独立影响。与先前分析的频繁染色体缺失的比较揭示了与磷酸酶和张力蛋白同源物缺失的密切关联。B7-H3单独或与其他标志物联合分析可能具有临床实用性，尤其是在ERG阴性前列腺癌亚组中。
B7-H3 is a member of the B7 superfamily of immune checkpoint molecules. B7-H3 up regulation has been linked to cancer development and progression in many tumors including prostate cancer. To clarify the potential utility of B7-H3 as a prognostic biomarker, B7-H3 expression was analyzed by immunohistochemistry in more than 17 000 prostate cancers. Normal prostatic glands were largely B7-H3 negative, while membranous B7-H3 immunostaining was seen in 47.0% of analyzed cancers. B7-H3 immunostaining was weak in 12.3%, moderate in 21.1% and strong in 13.5% of cases. High B7-H3 expression was associated with pT, Gleason score, lymph node metastasis, high Ki67 labeling index and early prostate-specific antigen recurrence (P < 0.0001 each). High B7-H3 expression was also linked to high androgen receptor expression andTMPRSS2:V-ets avian erythroblastosis virus E26 oncogene homolog (ERG)fusions (P < 0.0001 each). Multivariate analyses showed a strong independent prognostic impact of high B7-H3 expression in all cancers and in the ERG negative subgroup. Comparison with previously analyzed frequent chromosomal deletions revealed a close association withPhosphatase and Tensin Homologdeletions. Analysis of B7-H3, alone or in combination with other markers, might be of clinical utility, especially in the subgroup of ERG negative prostate cancers.